Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Nat Chem Biol. 2017 Nov 13;14(1):22–28. doi: 10.1038/nchembio.2517

Figure 5. Binary global metabolomics analysis of taurine co-treatment and evaluation of the impact of inhibition of taurine biosynthesis on OL differentiation.

Figure 5

(a) Binary global metabolomics analysis of the impact of taurine (Tau, 20 mM) supplementation on pre-myelinating OLs (day 3, D3) and OLs (day 6, D6) differentiated using T3 (1 µM). Numbers represent fold changes of metabolites, with values smaller than one suggesting downregulation and values larger than one suggesting upregulation. White indicates nondetected (i.e., below the limit of detection). Darker circles represent P < 0.05. (b) Taurine biosynthesis pathway highlighting the relationship to glycosphingolipid (GSL) biosynthesis and the impact of propargylglycine (PPG)-mediated inhibition of cystathionine γ-lyase on taurine and GSH production. (c) Quantification of MBP-positive OLs based on MBP immunofluorescence analysis on day 6 post-treatment with DMSO, miconazole (2 µM), benztropine (0.5 µM), or T3 (1 µM), following addition of PPG (10 µM), taurine (20 mM) or PPG (10 µM) and taurine (20 mM). Data are mean ± s.d. for the percentage of MBP-positive cells per well (n = 3 replicate cell cultures). ns, no significance; *P < 0.05; **P < 0.01; ****P < 0.0001.